帕金森病诊断及治疗策略研究新进展  

Research Progress in Diagnosis and Treatment of Parkinson’s Disease

作　　者：亓斐 王满侠[1] 马玉梅[1] 鲍彩彩 牛彦霞 QI Fei;WANG Manxia;MA Yumei;BAO Caicai;NIU Yanxia(Department of Neurology,the Second Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第二医院神经内科

出　　处：《医学综述》2019年第21期4261-4265,共5页Medical Recapitulate

基　　金：甘肃省国际合作基地项目(甘科外〔2017〕2号)

摘　　要：帕金森病(PD)是最常见的神经系统退行性疾病之一,随着人口老龄化进程的加快,PD发病率和致残率呈逐年上升趋势。诊断PD主要依靠临床症状和体征,寻找有助于PD临床前诊断的生物标志物或辅助检查方法对PD的诊断具有重要意义。目前,PD治疗侧重于多巴胺替代及缓解震颤症状,但不良反应较多,如长期使用左旋多巴产生的开-关现象,严重影响PD患者的生存质量。因此,有效缓解PD症状新药物的研发十分重要,对缓解PD症状起到关键作用,并对PD的临床治疗具有重要意义。Parkinson’s disease(PD)is one of the most common degenerative diseases of the nervous system.With the coming of the aging age of the population,its morbidity and disability rate are on the rise year by year.At present,the diagnosis of PD mainly depends on clinical symptoms and signs,and the search for biomarkers or auxiliary examinations helpful for preclinical diagnosis is of great significance for the diagnosis of diseases.PD treatment focuses on dopamine replacement and symptomatic relief,but current treatments can cause many adverse effects,for example,long-term use of levodopa can produce on-off drug wave phenomenon,seriously influencing PD patients’quality of life.Therefore,new drugs for effectively alleviating the symptoms of PD are of great significance for the clinical treatment of PD.

关 键 词：帕金森病 胰高血糖素样肽-1受体激动剂 酪氨酸肌酶抑制剂 红景天苷 免疫治疗 强直性脊髓电刺激 

分 类 号：R745.1[医药卫生—神经病学与精神病学]